 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 83,750 shares of the companys common stock to four new employees as inducement awards under the companys 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635c4. The st 